TITLE

Uptake of antiretroviral treatment among people living with HIV in London: ethnicity, gender and sexual orientation

AUTHOR(S)
Elford, J.; Ibrahim, F.; Bukutu, C.; Anderson, J.
PUB. DATE
June 2008
SOURCE
Sexually Transmitted Infections;Jun2008, Vol. 84 Issue 3, p176
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: To examine, by ethnicity, gender and sexual orientation, uptake of antiretroviral treatment among people living with HIV in London. Methods: Between June 2004 and June 2005, 1687 people living with HIV (73% response) receiving treatment and care in North East London National Health Service outpatient clinics completed a confidential, self administered, questionnaire. Respondents were asked whether they were currently taking HIV treatments (antiretroviral or combination therapy) Results: Overall, 73.7% (1057/1435) of respondents said they were currently taking HIV treatments: white men who have sex with men (MSM) 70.7%; ethnic minority MSM 70.9%; black African heterosexual women 75.0%; black African heterosexual men 80.8% (p<0.05). In all groups, taking HIV treatments was strongly associated with having a low CD4 cell count at diagnosis (p<0.001); 30.1% of white and ethnic minority MSM had a CD4 cell count less than 200 cells/mm³ at diagnosis compared with 53.1% of the black African heterosexual women and 66.3% of the black African heterosexual men (p<0.001). After adjusting for CD4 cell count at diagnosis, no significant differences in uptake of HIV treatments remained between the groups: MSM AOR 1.00 (reference group); black African heterosexual women AOR 1.15, 95% Cl 0.71 to 1.88, p = 0.6; black African heterosexual men AOR 0.88, 95% Cl 0.43 to 1.80, p = 0.7. Conclusion: Our analysis suggests that in London, once HIV infection is diagnosed, people from the two main risk groups—MSM (mostly white men) and black African heterosexual men and women—receive HIV treatment according to clinical need regardless of their ethnicity, gender or sexual orientation.
ACCESSION #
32802926

 

Related Articles

  • Chapter #4: Controlling HIV and AIDS. Gedatus, Gustav Mark // HIV & AIDS (0-7368-0281-9);2000, p28 

    The chapter focuses on the importance of knowing one's HIV status to control its effects and to protect others from the virus. Testing for HIV can be done confidentially or anonymously for complete privacy. HIV-positive people need to eat right, exercise, get plenty of rest, and avoid tobacco,...

  • Elvitegravir non-inferior to raltegravir in treatment-experienced patients.  // Infectious Disease News;Aug2011, Vol. 24 Issue 8, p12 

    The article focuses on a study which compared the effectiveness of once-daily elvitegravir and twice-daily raltegravir in treating HIV-1 infected patients.

  • HIV-associated early gastric adenocarcinoma successfully cured with surgery, and followed over eight years. Manfredi, Roberto; Sabbatani, Sergio; Fasulo, Giovanni // International Journal of STD & AIDS;Jul2007, Vol. 18 Issue 7, p501 

    An extremely rare case report of HIV-associated gastric adenocarcinoma surgically treated in the year 1998 in a 37-year-old male patient already HIV positive for 10 years, with a complete post-surgery disease-free follow-up of eight years, is described. An international literature search allowed...

  • Poly-L-Lactic Acid. Perry, Caroline M. // American Journal of Clinical Dermatology;2004, Vol. 5 Issue 5, p361 

    â–´ Poly-L-lactic acid, a synthetic biodegradable polymer, is available as an injectable intradermal implant for use in the correction and restoration of the signs of facial lipoatrophy in patients with HIV infection. â–´ In a 96-week noncomparative study in HIV-infected patients with...

  • TRIAL WILL EVALUATE CYCLOSPORINE.  // AIDS Patient Care & STDs;Mar1999, Vol. 13 Issue 3, p202 

    Announces the recruitment of HIV patients with CD4 cell counts above 500 for a phase II placebo-controlled study of low-dose cyclosporine. Anecdotal reports of the potential of the immunosuppressant as an HIV treatment; Duration of the trial.

  • Tipranavir cost effective in treatment-experienced HIV.  // PharmacoEconomics & Outcomes News;7/15/2006, Issue 507, p8 

    Discusses research being done on the cost effectiveness of tipranavir for treatment-experienced patients with HIV infections. Reference to a study by K. N. Simpson et al, published in the May to June 2006 issue of "Value in Health"; Range of the incremental cost-effectiveness ratio for...

  • How to Evaluate a Rise in Serum Lactate Levels in HIV-Infected Patients Undergoing Antiretroviral Therapy: Data From a Prospective, Case-Control Study. Manfredi, Roberto; Calza, Leonardo; Chiodo, Francesco // Journal of Applied Research;Summer2003, Vol. 3 Issue 3, p304 

    Objective: The goal of our study is to assess the frequency, risk factors, and features of hyperlactatemia in a cohort of about 1,000 patients with HIV disease. Methods and Results: In a prospective 6-month case-control study involving about 1,000 HIV-infected patients, a 35.9% crude frequency...

  • South Africans Win Some, Lose Some. Houlton, Sarah // Pharmaceutical Executive;Oct2003, Vol. 23 Issue 10, p24 

    Reports that the South African government has approved the provision of antiretroviral drugs to HIV-positive South Africans. Funding by the Global Fund to Fight AIDS, Malaria and Tuberculosis of an AIDS program in KwaZulu Natal.

  • Federal grant enables HIV testing, treatment in the Auga area.  // Biomedical Market Newsletter;3/21/2012, Vol. 21, p1 

    The article focuses on a question being asked by physician Cheryl Newman to every HIV-positive patient in order to maximize HIV patient's treatment.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics